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Objectives: To compare pulmonary perfusion parameters by means of dynamic perfusion mag-
netic resonance in patients affected by chronic obstructive pulmonary disease (COPD), during
and after acute exacerbation.
Methods: Fifteen patients were successfully evaluated with perfusional MRI during an acute
exacerbation of COPD and upon clinical stabilization. Inclusion criteria were a
PaCO2 > 45 mmHg and respiratory acidosis (arterial blood pH < 7.35) at admittance.
Results: In the acute phase a reduction of pulmonary blood flow (PBF) and pulmonary blood
volume (PBV), and a significant prolonging of the mean transit time (MTT) and time to peak
(TTP) were observed in all patients. In the stabilization phase a significant increase of PBF
and PBV and a significant reduction of MTT and TTP were observed in 6 patients; no significant
variations were observed in the other 9 patients.
Conclusion: 3D time-resolved contrast-enhanced MRI allows quantitative evaluation of pulmo-
nary regional perfusion in patients affected by COPD, identifying patients in which perfusion
defects are resolved in the clinical-stabilization phase.y to this paper and state: that it is not under consideration for publication anywhere else; that its
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876 G. Sergiacomi et al.This technique might allow the identification of patients in whom vasospasm may be the
main responsible of pulmonary hypoperfusion during acute COPD exacerbation, with potential
advantages on the clinical management of these patients.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
The evaluation of pulmonary perfusion plays a major role in
the study of lung function and in the understanding of pul-
monary pathophysiology. Changes in regional parenchymal
perfusion can be encountered in some lung diseases such as
pulmonary embolism, chronic obstructive pulmonary disease
(COPD), pulmonary hypertension and lung cancer [1e5].
Evaluation of regional lung perfusion may be used in the
differential diagnosis between different diseases by
demonstration of a characteristic perfusion pattern. More-
over, the evaluation of a specific pulmonary perfusion
pattern may be used to improve the therapy planning [6].
Several techniques have been used for the assessment of
pulmonary perfusion including lung perfusion scintigraphy
[7] and dynamic computed tomography [8]. Radionuclide
techniques based on intravenous administration of radio-
active macro-aggregates have been widely used for many
years and currently scintigraphy and SPECT represent the
gold standard [9]. These techniques, however, expose the
patient to ionizing radiations and have a reduced both
spatial and temporal resolution, which results in a reduced
anatomical definition and low functional sensitivity [10,11].
Early effective studies on pulmonary perfusional MR
were performed using angiographic sequences with para-
magnetic contrast [12e15]. The currently used techniques
are based on 2D and 3D Fast Field-Echo (FFE) dynamic se-
quences, and on Echo Planar Imaging (EPI) [5]. On this
basis, the aim of our study was to compare the pulmonary
perfusion parameters in patients during and after an acute
COPD exacerbation with hypercapnic syndrome, using dy-
namic perfusion magnetic resonance.Materials and methods
Patients
Fifteen patients affected by COPD were evaluated by per-
fusional MRI between October 2011 and July 2012 (12 men
and 3 women; age range: 65e78 yrs; mean age:
71.4  4.5 yrs). All participants had a diagnosis of moderate
to severe COPD according to the Global Initiative for
Obstructive Lung Disease classification [16] and had been
admitted to the emergency department under acute
exacerbation of chronic obstructive pulmonary disease
(AECOPD), and then referred to the pulmonary disease
department [17e19]. Overall clinical and laboratory ex-
aminations were evaluated by a pulmonologist. Inclusion
criteria were an arterial carbon dioxide tension (PaCO2)
greater than 45 mmHg and respiratory acidosis with arterial
blood pH of <7.35 [20,21]. All patients presented with
clinical signs suggestive of right heart failure. We excludedpatients with diagnosis of interstitial lung diseases primary
and secondary to collagen pathologies, exposure to drugs or
environmental toxics agents, cardiac diseases and history
of chest radiation therapy.
Functional MR was performed, for each patient, after
hospital admission during the acute respiratory distress
phase, and upon clinical stabilization before discharge.
Our Institutional Review Board approved the experimental
protocol and all patients were given an explanation of the
purpose of the study and provided written informed consent.
Perfusional MR imaging technique
MR imaging was performed with a 3.0 T MR scanner (Ach-
ieva 3 T; Philips Healthcare, Best e The Netherlands). A six-
element phased-array coil was used. A 20-gauge cannula
was positioned in the right antecubital vein and connected
to an electronic power injector (MR Spectris; Medrad,
Pittsburgh, PA).
After scout images were obtained, an inspiratory breath-
hold dynamic 3D time-resolved T1-weighted turbo field-
echo sequence was performed (repetition time 2.6 ms/
echo time 1.3 ms; flip angle: 10; turbo factor: 40; sensi-
tivity-encoding factor: 3; field of view of 435  326 mm;
reconstruction matrix 256  256; spatial resolution: 1.7 x
1.3 mm). All acquisitions were performed on axial plane
including both lungs. We covered a slab of 300 mm divided
in 30 over-contiguous partitions leading to a section thick-
ness of 5 mm. The first volume was acquired during breath-
hold before starting the contrast medium injection and was
used as reference for subtraction.
Eight milliliters (0.5 mmol/mL) of gadopentetate dime-
glumine (Magnevist; Bayer HealthCare, Wayne, NJ) was
injected at 4 mL/s, followed by 20 mL of saline solution
administered with the same flow rate. Image acquisition
was obtained without any delay since the beginning of the
injection of the contrast medium (delay time: Ø s).
The scan time for each 3D dataset was 1.5 s. Ten
consecutive sequences were performed in an overall time of
15 s of inspiratory breath-hold. Patients were asked to hold
their breath as long as possible during the data acquisition.
Cardiac triggering or respiratory gating was not used.
Data analysis
The color-coded perfusion maps were generated with a
workstation (ViewForum; Philips Healthcare, Best e The
Netherlands) and a radiologist and a pulmonologist in
consensus processed the acquisition data with the purpose
of calculating the signal intensity versus time (SI/t) curves,
obtained by the placement of Regions of Interest (ROIs).
Two lung-shaped ROIs were drawn defining the full extent
of both lungs, excluding the hilar vascular structures. A
Figure 2 Coronal quantitative color-coded perfusion maps in
a 69-year-old man with acute COPD exacerbation showing the
correct tracking of ROIs on both lungs, with exclusion of hilar
vascular structures. It’s important to note the presence of
areas with reduced/absent flow suggestive for pulmonary
hypoperfusion, with a pattern of peripheral mantel
distribution.
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the pulmonary artery as reference of pulmonary arterial
flow (Figs. 1 and 2). Subsequently, 6 ROIs (3 for each lung)
were plotted on different peripheral areas of the lung,
avoiding large vessels, for the evaluation of the regional
perfusion (Fig. 3). All the ROIs were placed with free hand
drawing, taking care to avoid areas whose signal was clearly
determined by motion artifacts. The data obtained by the 6
parenchymal ROIs were used, together with the lung-
shaped ones, to produce average perfusion data, less
dependent from physiological i.e., gravity blood stasis, and
pathological causes i.e., parenchymal consolidations, scar
tissues, bronchiectasis or emphysema bullae.
Initially, perfusion values obtained from the lung-shaped
ROIs were averaged with the median values calculated from
the 3 regional ROIs. Subsequently, these values were
averaged with the ones calculated from the contralateral
lung and normalized using the ROI put in the pulmonary
trunk.
The SI/t curves generated by measuring the signal in-
tensity in ROIs drawn in each patient before and after
medical therapy were analyzed in order to calculate the
perfusion data. The values of the SI/t curves calculated in
correspondence of the peripheral lung ROIs were normal-
ized to the values of the SI/t curves of the ROI drawn at the
trunk of the pulmonary artery, in order to avoid artifacts
due to the different impedances of pulmonary blood flow.
In order to extract quantitative indices such as Pulmo-
nary Blood Flow (PBF; mL/100 mL of lung tissue/min),
Pulmonary Blood Volume (PBV; mL/100 mL of lung tissue),
Mean Transit Time (MTT; s) and Time To Peak (TTP; s), SI/tFigure 1 Contrast-enhanced perfusion MRI (TR/TE, 2.6/1.3)
with a temporal resolution of 1.5 s after application of gado-
pentetate dimeglumine in a 63-year-old man with acute COPD
exacerbation. Coronal maximum intensity projection (MIP)
image showing enhancement of lung arterial vessels. Two ROIs
(L1 and L2) were drawn in order to calculate SI/t curves,
defining the full extent of both lungs, excluding the hilar
vascular structures. A third ROI (L3) was drawn at the trunk of
the pulmonary artery in order to normalize the values of SI/t
curves of the peripheral and avoiding artifacts due to the
different impedances of pulmonary blood flow.curves were fitted to a gamma variate function using an
algorithm described in previous studies, such as the ones by
HatabueTadamura; UematsueLevin; JangeOh [11,22,23].
Patients in which a normalization of at least two
perfusion parameters was observed in the clinical-stabili-
zation phase MR composed Group 1; patients in which a
normalization of less than two perfusion parameters
resulted normalized in the clinical-stabilization phase MR
composed Group 2. Normalization of a perfusion parameter
was defined as a value comprised in the range of the control
group described in a previous reports [24,25].
Statistical analysis
The comparison of each perfusion parameter between the
two observations for each group of patients was performed
using a paired Student “t” test; descriptive graphs, P value
and R2 (r) were obtained using GraphPad Prism 5.0
(GraphPad Software, Inc. La Jolla, CA, USA).
Results
Dynamic pulmonary MR angiography was successfully ac-
quired in all enrolled subjects. The functional MRI evalua-
tion of pulmonary perfusion performed during acute clinical
phase demonstrated in all patients a reduction of PBF
(Mean: 63.47  8.983 mL/100 mL/min; 95% C.I.
58.49e68.44) and PBV (4.653  0.9125 mL/100 mL; 95% C.I.
4.148e5.159), and a significant prolonging of MTT (Mean:
7.593  1.706 s; 95% C.I. 6.649e8.538) and TTP (Mean:
4.740  1.093 s; 95% C.I. 4.135e5.345), compared with the
normal physiologic values [14,24,25]. The evaluation of
pulmonary perfusion acquired performed during the clinical
stabilization compared to those acquired in the acute phase
Figure 3 Coronal quantitative color-coded perfusion maps in
a 62-year-old woman with acute COPD exacerbation. 6 ROIs (3
for each lung) were plotted on different peripheral areas of
both lungs (L1eL3: right lung; L4eL6: left lung), avoiding large
vessels, for the evaluation of the regional peripheral perfusion.
Figure 4 The graphic shows modification of functional paramete
acute COPD exacerbation in 6 patients (group 1).
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6.087  1.828 mL/100 mL; 95% C.I. 5.074e7.099, difference
P Z 0.0382) and TTP (Mean: 3.747  1.056 s; 95% C.I.
3.162e4.331, difference P < 0.0142); no significant differ-
ences were observed among the mean PBF
(91.8  38.93 mL/100 mL/min 95% C.I. 70.24e113.4,
PZ 0.0638) and PBV (Mean: 7.367  4.577 mL/100 mL 95%
C.I. 4.832e9.901, difference P Z 0.05) values.
In 6 patients the functional MRI evaluation of pulmonary
perfusion performed during clinical-stabilization phase
showed a normalization of all the perfusion parameters,
with a significant increase of PBF (136.3  14.4 mL/100 mL/
min; 95% CI: 121.2, 151.5; R2 Z 0.97; Pvalue < 0.0001) and
PBV (11.8  4.2 mL/100 mL; 95% CI: 7.4, 16.3; R2 Z 0.8;
Pvalue Z 0.0059) and a significant reduction of MTT
(4.6  1 s; 95% CI: 3.6, 5.7; R2Z 0.96; Pvalue < 0.0001) and
TTP (2.8  0.7 s; 95% CI: 2, 3.5; R2Z 0.84; PvalueZ 0.0034);
these patients were defined as Group 1 (Fig. 4). The
remaining 9 patients showed no significant changes in PBF
(62.1  6.5 mL/100 mL/min; 95% C.I.: 57.1, 67.1;
R2 Z 0.06; Pvalue < 0.4858), PBV (4.39  0.7 mL/100 mL;
R2 Z 0.0005; 95% CI: 3.8, 4.9; Pvalue < 0.9493) and no sig-
nificant reduction of MTT (7  1.65 s; R2Z 9.283e-005; 95%
CI: 5.7, 8.3; Pvalue Z 0.9789) and TTP (4.39  0.7 s;rs such as PBF, PBV, MTT and TTP obtained during and after the
Acute COPD exacerbation 879R2 Z 0.1029; 95% CI: 3.8, 4.9; Pvalue Z 0.3663) were
observed; these patients were defined as group 2 (Fig. 5). A
comparison between the “acute phase” and the “clinical-
stabilization phase” values between the two groups is
shown in Table 1.
Discussion
Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality worldwide, with an
increasing prevalence during the past decades. One
established complication of COPD is the development of
pulmonary hypertension (PH), which leads to right ven-
tricular enlargement and hypertrophy [26]. When the
adaptive mechanisms of right ventricular dilatation and
hypertrophy cannot compensate for the hemodynamic
burden, right heart failure, with poor prognosis, occurs
[27]. Typically, pH appears when airflow limitation is severe
and is associated with chronic hypoxemia.
The normal gas exchange in the lung is provided by the
perfect balance between ventilated and perfused areas
which is pathologically altered in COPD. The consequent
hypoxic vasoconstriction of pulmonary vessels, thatFigure 5 The graphic shows modification of functional parameter
acute COPD exacerbation in 9 patients (group 2).represent the main mechanism to attempt to maintain a
correct V/Q ratio, leads to a reduction of perfusion in non-
ventilated lung areas. A second adjustment mechanism of
V/Q ratio is the pulmonary hypercapnic vasoconstriction,
opposite to the systemic hypercapnic vasodilation [28,29].
Furthermore some abnormalities, including pulmonary
vascular remodeling, reduction of pulmonary vessels and
pulmonary thrombosis, which influence pulmonary arterial
pressure determining the increase in pulmonary vascular
resistance index (PVRI) and the onset of pulmonary hyper-
tension and right heart failure, are commonly found in
COPD [26].
The increased PVRI is the result of the combination or
irreversible and potentially reversible mechanisms. Arterial
obstruction, obliteration and remodeling are accountable
for the irreversible component, while active increases in
vascular tone for the reversible one, which, in some cases,
may represent more than 50% of PVRI and can be poten-
tially susceptible to pharmacological treatment [26,27].
3D time-resolved MR angiography allows the evaluation
of pulmonary hemodynamic parameters, such as PBF, PBV,
MTT and TTP, which significantly correlate with the same
parameters obtained through invasive techniques [30].s such as PBF, PBV, MTT and TTP obtained during and after the
Table 1 Values of PBF, PBV, MTT and TTP of Group 1 and Group 2 patients, evaluated with dynamic pulmonary MR angiography
during the acute respiratory distress phase and during the clinical-stabilization phase.
Group 1a Group 2b
Acute phase Clinical stabilization Acute phase Clinical stabilization
PBF (mL/100 mL of
lung tissue/min)
64.3  12.3
95% C.I.: 51.4e77.3
136.3  14.4
95% C.I.: 121.2e151.5
62.9  6.7
95% C.I.: 57.7e68
62.1  6.5
95% C.I.: 57.1e67.1
PBV (mL/100 mL of
lung tissue)
5  1
95% C.I.: 3.9e6.1
11.8  4.2
95% C.I.: 7.4e16.3
4.4  0.8
95% C.I.: 3.8e5
4.39  0.7
95% C.I.: 3.8e4.9
MTT (s) 8.4  1.5
95% C.I.: 6.8e10
4.6  1
95% C.I.: 3.6e5.7
7  1.6
95% C.I.: 5.7e8.3
7  1.65
95% C.I.: 5.7e8.3
TTP (s) 4.9  1.1
95% C.I.: 3.8e6.1
2.8  0.7
95% C.I.: 2e3.5
4  1.1
95% C.I.: 3.7e5.4
4.39  0.7
95% C.I.: 3.8e4.9
PBF Z pulmonary blood flow; PBV Z pulmonary blood volume; MTT Z mean transit time; TTP Z time to peak.
a Group 1 identifies the 6 patients in which an improvement of the perfusion parameters was observed in the clinical-stabilization
phase.
b Group 2 identifies the 9 patients in which no significant changes in the perfusion parameters were observed between the acute and
the stabilization phase.
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arterial quantitative indices using 3D time-resolved MR
angiography in patients affected by COPD, during the acute
hypercapnic syndrome phase and upon the clinical-stabili-
zation phase. In all patients a significant reduction of PBF
and PBV during the acute hypercapnic syndrome was
documented, suggesting the presence of pulmonary hypo-
perfusion with a characteristic peripheral mantel distribu-
tion pattern. In these patients, moreover, MTT and TTP
were significantly prolonged, compared to the normal
physiologic values reported in the literature [24,25].
Previous studies [11,25] described a reduced MTT in
patients affected by COPD, which appear to be in contrast
with our finding of an increased MTT. We believe that this
discrepancy may be a result of the fact that the patients
evaluated in this study were experiencing an acute COPD
exacerbation with hypercapnic syndrome, which may have
determined a significant increase of the pulmonary arterial
pressure. Consistently with that, pulmonary hypertension
has been shown to be associated with a prolonged MTT [24].
Two groups of patients, which presented different
normalization of SI/t-derived values in the functional MRI
executed during the clinical-stabilization phase, were
identified. In group 1 a significant increase of PBF and PBV
with a normalization trend of MTT and TTP values was
observed, suggesting in these patients the prevalence of
reversible mechanisms accountable for hypoperfusion i.e.,
peripheral hypoxic/hypercapnic vasoconstriction. In group
2, no substantial variation of PBF, PBV, MTT and TTP values
between the acute phase and the clinical-stabilization
phase MR was observed. This observation suggest the
presence of underlying irreversible mechanisms in patients
belonging to this group, possibly due to extensive vascular
remodeling or thromboembolic events.
Previous studies demonstrate the feasibility at 3.0 T of
3D contrast-enhanced MR angiography, which allows a
detailed morphological evaluation of the pulmonary
vasculature and provides hemodynamic functional infor-
mation [30,31]. Higher SNR at 3.0 T is an important element
for increasing spatial resolution and is likely to improve
visualization of small blood vessel segments [32,33].In patients presenting severe pulmonary function
impairment, poor breath-hold capability may result in un-
derestimation or overestimation of regional perfusion and
regional pulmonary function due to motion artifacts [24].
Our results demonstrate the feasibility of using 3D time-
resolved contrast-enhanced MRI to quantitatively evaluate
pulmonary regional perfusion in patients affected by COPD.
Lung parenchyma has a very short T2 value ranging from
0.9 to 2.2 ms, due to the multiple interface of air and soft
tissue produced by the alveoli, which cause large local
magnetic field gradients and dephase the MR signal
[9,30,34]; thus we attempted to obtain a better MR signal
from the lung parenchyma by using a 3.0 T field, which
provides a higher SNR compared with lower fields such as
1.5 T, and performed a transaxial 3D T1-weighted turbo
field-echo sequence, which need a short echo time
(1.3 ms). The angiographic technique described in this
study yields time-resolved images of the pulmonary circu-
lation, from which physiologic information can be calcu-
lated. To reduce acquisition times and improve temporal
and spatial resolution, we used the sensitivity-encoding
technique [35], which improves the compliance of pa-
tients with decreased respiratory reserve, unable to
perform prolonged and repeated apnea, by reducing the
overall scan time. Indeed the poor breath-hold capability
represents a limit in the functional evaluation with dynamic
MR imaging, and therefore it could have led to a possible
bias due to selection towards more cooperative patients.
A reduced administration of medium contrast is a further
advance of the acquisition technique used in this study. In
fact, when using ultra-short echo-time sequences, the
administration of gadolinium-based contrast agent de-
termines an increase of the MR signal, which reduces the
magnetic susceptibility effects [12,13]. As described in
previous reports, we administered a low dose (8 mL) of
contrast agent. A high dose (20 or 40 mL) of contrast agent
has been shown to produce the most intense parenchymal
enhancement, while a low dose (5 mL) has been shown to
provide a better recirculation imaging [12,13]. As to avoid
artifacts in the perfusion parameters calculation, an
adequate molality (0.5 mmol/mL) and an intermediate
Acute COPD exacerbation 881dosage (8 mL) of contrast media were chosen. As
mentioned in previous reports [36], these molality and
volume combination determine an average contrast media
dose of 0.057 mmol/kg of body weight, which is sufficient
to avoid artifacts in the calculation of the perfusion pa-
rameters determined by the linear correlation between
contrast media concentration and signal intensity deter-
mined by low contrast doses.
Our study is characterized by some limitations. In first
place, the number of patients included was small, which
makes a further evaluation of a larger cohort of patients
required for more accurate conclusions. A second limitation
is the quite long inspiratory breath-hold used in this study
which, although all enrolled patients were able to complete
the MRI evaluation, may not be feasible in all patients with
impaired respiratory compliance in a real life clinical
setting. Finally, the evaluation of pulmonary perfusion by
MR may be influenced by volume variations such as those
occurring in inspiratory and expiratory breath-hold. Pul-
monary perfusion during breath-hold depends on the
inspiratory level, in fact higher perfusion is commonly
observed at expiratory breath-hold, thus making a strict
breath-hold standardization protocol and patients compli-
ance mandatory for the good accuracy of this diagnostic
technique [37].
In conclusion, 3D time-resolved contrast-enhanced MRI
is useful for a quantitative evaluation of pulmonary regional
perfusion in patients affected by COPD. The comparative
evaluation of perfusion parameters obtained during an
acute COPD exacerbation and upon clinical stabilization,
may be useful in the identification of patients in whom the
hypoperfusion due to vasospasm is the main responsible of
pulmonary hypoperfusion during acute COPD exacerbation
with potential advantages on the clinical management of
these patients.
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